Literature DB >> 21900531

Can HIV p24 be a suitable scaffold for presenting Env antigens?

Luigi Buonaguro, Maria Tagliamonte, Maria Lina Tornesello, Franco M Buonaguro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21900531      PMCID： PMC3209041          DOI： 10.1128/CVI.05326-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


× No keyword cloud information.
  36 in total

1.  Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.

Authors:  Anna Laura Ross; Andreas Bråve; Gabriella Scarlatti; Amapola Manrique; Luigi Buonaguro
Journal:  Lancet Infect Dis       Date:  2010-05       Impact factor: 25.071

2.  Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.

Authors:  Christian H Bell; Ralph Pantophlet; André Schiefner; Lisa A Cavacini; Robyn L Stanfield; Dennis R Burton; Ian A Wilson
Journal:  J Mol Biol       Date:  2007-11-13       Impact factor: 5.469

Review 3.  The structural biology of HIV assembly.

Authors:  Barbie K Ganser-Pornillos; Mark Yeager; Wesley I Sundquist
Journal:  Curr Opin Struct Biol       Date:  2008-04-09       Impact factor: 6.809

4.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

5.  Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.

Authors:  J M Binley; P J Klasse; Y Cao; I Jones; M Markowitz; D D Ho; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

6.  Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects.

Authors:  D Noah Sather; Leonidas Stamatatos
Journal:  Vaccine       Date:  2010-05-26       Impact factor: 3.641

7.  CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease.

Authors:  Eli Boritz; Eric L Rapaport; Thomas B Campbell; John R Koeppe; Cara C Wilson
Journal:  Virology       Date:  2006-12-13       Impact factor: 3.616

8.  Decline of anti-p24 antibody precedes antigenaemia as correlate of prognosis in HIV-1 infection.

Authors:  S M Forster; L M Osborne; R Cheingsong-Popov; C Kenny; R Burnell; D J Jeffries; A J Pinching; J R Harris; J N Weber
Journal:  AIDS       Date:  1987-12       Impact factor: 4.177

9.  X-ray structures of the hexameric building block of the HIV capsid.

Authors:  Owen Pornillos; Barbie K Ganser-Pornillos; Brian N Kelly; Yuanzi Hua; Frank G Whitby; C David Stout; Wesley I Sundquist; Christopher P Hill; Mark Yeager
Journal:  Cell       Date:  2009-06-11       Impact factor: 41.582

10.  Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.

Authors:  Javier Guenaga; Pia Dosenovic; Gilad Ofek; David Baker; William R Schief; Peter D Kwong; Gunilla B Karlsson Hedestam; Richard T Wyatt
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240
View more
  2 in total

1.  Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo.

Authors:  Bernard Verrier; Stéphane Paul; Céline Terrat; Liza Bastide; Agathe Ensinas; Capucine Phelip; Blandine Chanut; Laura Bulens-Grassigny; Fabienne Jospin; Christophe Guillon
Journal:  Front Immunol       Date:  2017-06-30       Impact factor: 7.561

2.  HIV p24 as scaffold for presenting conformational HIV Env antigens.

Authors:  Maria Tagliamonte; Daniela Marasco; Alessia Ruggiero; Angelo De Stradis; Maria Lina Tornesello; Maxim Totrov; Franco Maria Buonaguro; Luigi Buonaguro
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.